With nearly a third of patients post-myocardial infarction (MI) developing heart failure, prevention is very important, said Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute.
Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute, explains the goals and patient population included in the EMPACT-MI trial.
Presented at the European Society of Cardiology (ESC) Congress 2023, EMPACT-MI is testing the safety and benefit of empagliflozin to reduce heart failure hospitalization or all-cause mortality in patients post myocardial infarction (MI).
Transcript
Can you give our audience an overview of your presentation on the EMPACT-MI trial?
There has been really no therapy that has shown risk reduction in post-MI heart failure development. We do know that once you develop heart failure, your 5-year mortality risk equals or exceeds about 50%, so anything to prevent heart failure is really important and myocardial infarction is one of the biggest risk factors. The data would suggest—epidemiologic data—that a quarter to a third of the patients post-MI develop heart failure, so prevention of heart failure is really, really important.
SGLT2 inhibitors have been shown to prevent heart failure in patients with CKD [chronic kidney disease] and diabetes, and MI patients are sort of an enriched population, but (A) we need to prove it, but (B) there are safety concerns also. The post-MI patients get procedures, an [intravenous] contrast, a new RAAS [renin-angiotensin-aldosterone system] inhibitor, a new MRA [mineralocorticoid receptor antagonist], and now SGLT2 inhibitor, so we need to see what the safety and what the benefit profile is.
That was being tested in the EMPACT-MI trial, a large trial, 6000 patients, about three-fourths STEMI [ST-elevation MI patients] and about one-fourth non-STEMI patients enriched for heart failure. So either new onset [MI], drop in EF [ejection fraction], or signs or symptoms of congestion. People with history of heart failure [prior to MI] were excluded. The trial has completed enrollment, is in the follow-up phase, and anxiously awaiting results and we'll get the results hopefully pretty soon in the next few months.
This transcript has been lightly edited for clarity.
Best of Managed Care Cast: Top 5 Episodes From the First Half of 2025
July 18th 2025These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.
Read More
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
July 1st 2025Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Read More